We are live on ! Find out more
FP

Flagship Pioneering Portfolio holdings

AUM $1.54B
1-Year Est. Return 86.39%
This Fund
S&P 500
This Quarter Est. Return
-11.42%
1 Year Est. Return
+86.39%
3 Year Est. Return
-13.28%
5 Year Est. Return
-50.7%
10 Year Est. Return
+414.55%
AUM
$2.57B
AUM Growth
-$559M
Cap. Flow
+$16.6M
Cap. Flow %
0.64%
Top 10 Hldgs %
99.98%
Holding
12
New
–
Increased
1
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
OMGA
Omega Therapeutics, Inc. Common Stock
OMGA
+$23.1M

Top Sells

Rank Stock Value
1
RUBY
Rubius Therapeutics, Inc
RUBY
+$6.55M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNA icon
1
Moderna
MRNA
$57.4B
$1.98B 76.91%
12,886,743
– –
OMGA
2
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$176M 6.85%
29,225,579
+3,323,310
+13% +$23.1M
MCRB icon
3
Seres Therapeutics
MCRB
$46.2M
$131M 5.09%
1,155,852
– –
SANA icon
4
Sana Biotechnology
SANA
$946M
$112M 4.35%
34,239,018
– –
FHTX icon
5
Foghorn Therapeutics
FHTX
$245M
$78.6M 3.05%
12,674,120
– –
DNLI icon
6
Denali Therapeutics
DNLI
$3.26B
$60.4M 2.35%
2,619,968
– –
AXLA
7
DELISTED
Axcella Health Inc. Common Stock
AXLA
$14M 0.55%
1,170,062
– –
SGTX
8
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
$9.65M 0.37%
797,721
– –
EVLO
9
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$9.11M 0.35%
2,521,366
– –
SYRS
10
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$2.65M 0.1%
993,848
– –
CDAK
11
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
$618K 0.02%
3,540,636
– –
RUBY
12
DELISTED
Rubius Therapeutics, Inc
RUBY
– –
-38,506,526
Closed -$6.55M

Similar funds

SPC
Stony Point Capital New York $1.54B AUM 54.05% 1-Year Est. Return
AWC
Abundance Wealth Counselors State College, Pennsylvania $1.54B AUM 31.07% 1-Year Est. Return
SMC
Smith, Moore & Co Clayton, Missouri $1.54B AUM 24.82% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.54B AUM 30.95% 1-Year Est. Return
BOF
Bank of Finland Helsinki, Finland $1.54B AUM 15.84% 1-Year Est. Return
KCM
Kanawha Capital Management Richmond, Virginia $1.54B AUM 21.3% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.54B AUM 27.61% 1-Year Est. Return
HCM
Hollencrest Capital Management Newport Beach, California $1.54B AUM 30.1% 1-Year Est. Return

Flagship Pioneering's Q1 2023 Portfolio in Review

As of Q1 2023, Flagship Pioneering held 12 positions worth $2.57B, down 18% from $3.13B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Flagship Pioneering's Q1 2023 filing shows 1 increased and 1 closed positions. The largest sale was Rubius Therapeutics, Inc, an estimated $6.55M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Flagship Pioneering added most to Omega Therapeutics, Inc. Common Stock in Q1 2023, an estimated $23.1M increase.
  • Flagship Pioneering fully exited Rubius Therapeutics, Inc in Q1 2023, selling an estimated $6.55M.
  • Flagship Pioneering's ten largest holdings make up 100% of its $2.57B portfolio in Q1 2023.
  • Flagship Pioneering opened 0 new positions and closed 1 in Q1 2023.
  • Flagship Pioneering's portfolio value fell 18% quarter-over-quarter to $2.57B.

Based on Flagship Pioneering's 13F filing for Q1 2023, filed 15 May 2023.